The National Cancer Institute (NCI) is sponsoring this conference to: Examine when, where, and how the measurement of patient-reported outcomes (PROs), such as health-related quality of life (HRQOL), in cancer trials can yield valuable information for decisions about cancer care, third-party reimbursement, and drug approval. Identify "best practices" for the application of PRO measures in a range of cancer clinical trials (treatment and symptom management) through a critical examination of case studies developed expressly for the conference. Serve as a platform for informing the NCI Clinical Trials Working Group implementation process to ensure that the most important quality-of-life studies can be initiated in a timely manner in association with NCI-sponsored clinical trials. Inform the research agenda on improving the application of PRO measures in clinical trials generally. The purpose of this meeting is to: (a) determine what we know about the use and value of HRQOL in trials; (b) identify the challenges to more frequent or extensive application; and (c) identify the research studies and application projects that would enhance the decision-relevance of HRQOL measurement in trials. Scientific Program Committee Members
Deborah Watkins Bruner, Ph.D. University of Pennsylvania Laurie Burke, R.Ph., M.P.H. Food and Drug Administration Steven Clauser, Ph.D. National Cancer Institute Andrea Denicoff, R.N., B.S.N., M.S.N., A.N.P. National Cancer Institute Patricia Ganz, M.D. University of California - Los Angeles Kathleen Gondek, Ph.D. Bayer Corp Joseph Lipscomb, Ph.D. (Chair) Emory University	Lori Minasian, M.D., F.A.C.P. National Cancer Institute Ann O'Mara, Ph.D., R.N. National Cancer Institute Bryce Reeve, Ph.D. National Cancer Institute Dennis Revicki, Ph.D. The MEDTAP Institute at UBC Julia Rowland, Ph.D. National Cancer Institute Ted Trimble, M.D. National Cancer Institute
* The American Cancer Society is providing the lunches for the conference.